May 01, 2026 a 08:38 pm
CNC: Analysts Ratings - Centene Corporation
Centene Corporation, a leader in the healthcare industry, has shown varying analyst ratings over the past months. The company is consistently assessed by a significant number of analysts who express moderately cautious optimism about its stock. Despite recent trends indicating shifts towards more 'Hold' ratings, analysts generally maintain confidence in its potential.
Historical Stock Grades
The latest ratings from analysts include a wide spread of opinions, with a notable increase in 'Hold' ratings suggesting a level of caution or anticipated stability within the stock.
| Recommendation | Number of Analysts | Score Visualization |
|---|---|---|
| Strong Buy | 2 | |
| Buy | 5 | |
| Hold | 12 | |
| Sell | 1 | |
| Strong Sell | 0 |
Sentiment Development
The sentiment analysis over the past few months shows subtle but noticeable changes in the distribution of analyst recommendations:
- The 'Hold' category has seen a gradual increase, reflecting a cautious market stance.
- There is a reduction in 'Strong Buy' ratings from earlier data, indicating waned aggressive bullish sentiment.
- Despite fluctuations, 'Buy' recommendations have remained relatively stable.
Percentage Trends
Recent trends in percentage allocation of analyst ratings have highlighted significant shifts:
- 'Hold' recommendations have grown from approximately 25% to 60% over the past year.
- The 'Strong Buy' segment has decreased over time, reinforcing a more conservative analyst outlook.
- Overall optimism ('Buy' + 'Strong Buy') has been balanced by increasing neutral ('Hold') positions.
- The shifts suggest an evolving sentiment towards market stabilization rather than growth.
Latest Analyst Recommendations
The most recent analyst recommendations are critical in understanding market perceptions:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-04-29 | Buy | Buy | Truist Securities |
| 2026-04-29 | Outperform | Outperform | Oppenheimer |
| 2026-04-29 | Overweight | Neutral | Cantor Fitzgerald |
| 2026-04-29 | Buy | Underperform | B of A Securities |
| 2026-04-29 | Overweight | Overweight | Barclays |
Analyst Recommendations with Change of Opinion
Recommendations where analysts have shifted their stance provide deeper insights:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-04-29 | Overweight | Neutral | Cantor Fitzgerald |
| 2026-04-29 | Buy | Underperform | B of A Securities |
| 2026-01-05 | Overweight | Equal Weight | Barclays |
| 2025-07-28 | Neutral | Overweight | Cantor Fitzgerald |
| 2025-07-23 | Equal Weight | Overweight | Wells Fargo |
Interpretation
The analysis of recent analyst recommendations reveals a mixed sentiment towards Centene Corporation's stock. Although some level of optimism remains, the increase in 'Hold' ratings suggests a cautious sentiment, indicating possible concerns about the company's growth or market conditions. However, the stability of 'Buy' and instances of upgraded opinions imply ongoing trust in the company's fundamental strength. Overall, the analyst community seems to be hedging against uncertainties while recognizing potential upside.
Conclusion
Centene Corporation remains a solid player in the healthcare sector with a generally favorable analyst outlook. While the recent decline in 'Strong Buy' ratings points to moderated bullish sentiment, consistency in 'Buy' recommendations and absence of 'Strong Sell' ratings suggest stable confidence. Analysts appear to be repositioning outlooks, balancing between caution and optimism amid an evolving market backdrop. Future developments in the healthcare landscape and regulatory environment will be pivotal in shaping forthcoming perceptions.